Colorectal Carcinoma, Liver Metastasis
Conditions
Keywords
Liver metastasis, Colorectal carcinoma, Unresectable, Borderline resectable, Initially unresectable
Brief summary
This prospective database has two main objectives; * to evaluate the complication rates, 30-day and 90-day mortality from different surgical strategies for unresectable, borderline resectable or initially unresectable liver metastasis from colorectal cancer. * to establish baseline quality parameters for different surgical strategies for unresectable, borderline and initially unresectable colorectal liver metastasis (CRLM) patients.
Interventions
OTHEREvaluation of treatment for liver metastasis
Sponsors
European Society of Surgical Oncology
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* With histologically proven colorectal adenocarcinoma with liver metastasis. * With unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer assessed by a clinician or by a multi-disciplinary tumor board (MDT). * Unresectable is defined as no possibility of completely resecting all tumor due to size, location or number of deposits. * Borderline is defined as potentially operable but technically or biologically more challenging to resect as evaluated by the MDT. * Initially unresectable is defined as metastasis that have been down-sized after conversion chemotherapy and evaluated by the MDT to be resectable * discussed by a multidisciplinary team before surgery. * Participants of the MDT must include at least one liver surgeon, one radiologist and one oncologist. They will determine the resectability of the CRLM according to local practice. * With a possibility of a surgical procedure (resection with or without portal vein embolization, intraoperative local ablative technique or a combined approach) assessed during the MDT. * Age ≥ 18 years. * Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
Exclusion criteria
* Any psychological, familial, or sociological condition potentially hampering understanding of the research project. * Any other malignancy other than in situ carcinoma of the cervix or non-melanoma skin cancer (unless there has been a disease-free interval of at least 5 years)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of post-operative complications | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival after 2 years of follow-up | 3 years |
| Progression free survival at 2 years | 3 years |
| Number of post-operative complications in the first 50 patients compared to the second 50 patients | 1 year |
Countries
Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Serbia, Spain, Sweden, Switzerland, United Kingdom
Outcome results
None listed